Details

Autor(en) / Beteiligte

• Perkins, Rebecca B
• Guido, Richard S
• Castle, Philip E
• Chelmow, David
• Einstein, Mark H
• Garcia, Francisco
• Huh, Warner K
• Kim, Jane J
• Moscicki, Anna-Barbara
• Nayar, Ritu
• Saraiya, Mona
• Sawaya, George F
• Wentzensen, Nicolas
• Schiffman, Mark

Titel

2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023

Ist Teil von

• Journal of lower genital tract disease, 2024-01, Vol.28 (1), p.3-6

Ort / Verlag

United States

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.